Denali Therapeutics (STU:4DN) ROE % Adjusted to Book Value : -16.16% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics ROE % Adjusted to Book Value?

Denali Therapeutics's ROE % for the quarter that ended in Mar. 2024 was -32.80%. Denali Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 2.03. Denali Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -16.16%.

Denali Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Denali Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics ROE % Adjusted to Book Value Chart

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.82

1.04

-5.17

-9.34

-4.78

Denali Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-13.67	20.17	-13.42	-15.21	-16.16

Competitive Comparison of Denali Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Denali Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Denali Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's ROE % Adjusted to Book Value falls into.

Denali Therapeutics ROE % Adjusted to Book Value Calculation

Denali Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-13.80%	/	2.89
	=	-4.78%

Denali Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-32.80%	/	2.03
	=	-16.16%

Denali Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (STU:4DN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

DNLI:USA

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics (STU:4DN) Headlines

No Headlines